Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial

BACKGROUND: Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin depletion with longitudinal reductions in NMOSD activity aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Jeffrey L., Aktas, Orhan, Rees, William A., Smith, Michael A., Gunsior, Michele, Yan, Li, She, Dewei, Cimbora, Daniel, Pittock, Sean J., Weinshenker, Brian G., Paul, Friedemann, Marignier, Romain, Wingerchuk, Dean, Cutter, Gary, Green, Ari, Hartung, Hans-Peter, Kim, Ho Jin, Fujihara, Kazuo, Levy, Michael, Katz, Eliezer, Cree, Bruce A.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664402/
https://www.ncbi.nlm.nih.gov/pubmed/36370634
http://dx.doi.org/10.1016/j.ebiom.2022.104321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664402/
https://www.ncbi.nlm.nih.gov/pubmed/36370634
http://dx.doi.org/10.1016/j.ebiom.2022.104321

Ejemplares similares